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Aim: To determine the diagnostic efficacy of the size criteria for the detection of metastatic lymph nodes
(LN) in patients with hilar cholangiocarcinoma (HCCA).
Introduction: LN metastasis is one of the most significant independent prognostic factors in patients
with HCCA. Presently, in spite of the well known lack of sensitivity and specificity, one of the most used
clinical criteria for nodal metastases is LN size.
Methods: Pathological slides of 147 patients who had undergone exploration for HCCA were assessed.
The size (maximum and short axis diameter) of each single node was retrieved from the pathology report
or measured from a section on the glass slide using a stereo microscope and a calibrated ruler integrated
in the software. When a metastatic lesion was detected, the proportion of the lesion in relation to LN size
was estimated.
Results: Out of 147 patients, 645 LN were retrieved and measured. In all, 106 nodes (16%) showed
evidence of metastasis. The proportion of positive nodes was 8% in nodes <5 mm and 37% in nodes
>30 mm. Ten per cent of LN smaller than 10 mm were positive, whereas only 23% of LN larger than
10 mm were metastastically involved. No clear cut-off point could be found. Similar results were found for
the short axis diameter. In 50% of positive LN, the metastatic lesion accounted for 10% or less of the LN
size.
Conclusion: No cut-off point could be determined for accurately predicting nodal involvement. There-
fore, imaging studies should not rely on LN size when assessing nodal involvement.
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Introduction
The incidence of nodal involvement in resected specimens of
patients with hilar cholangiocarcinoma (HCCA) has been
reported to range from 30% to more than 50%.1–3 Lymph node
(LN) metastasis is one of the most significant independent prog-
nostic factors in patients with HCCA4–10. HCCA patients with
nodal involvement beyond the hepatoduodenal ligament are
currently considered unresectable.11,12 Hence, correct pre-
operative and operative assessment of LN status is of crucial
importance. Presently, in spite of the well known lack of sensitivity
and specificity, one of the most used clinical criteria for nodal
metastases is LN size. Moreover, the sizes of the maximum diam-
eter or the short-axis diameter are commonly measured. Although
enlarged regional LN on imaging studies are usually interpreted as
metastases, there is no data which supports this interpretation. In
addition, most patients with HCCA present with jaundice and in
many cases with cholangitis. Consequently, LN size may also beThis paper was presented at the EAHPBA 2011 meeting in Cape Town.
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increased as a result of local inflammation and infection, further
impeding the correct assessment of nodal status.
A number of studies have addressed the accuracy of several
imaging techniques, including ultrasound, computed tomogra-
phy (CT), magnetic resonance imaging (MRI) and positron
emission tomography (PET)13–16 for LN staging in HCCA.
Unfortunately, these studies have a major drawback, because
they correlate nodal positivity on a patient basis, rather than on
a nodal basis. In other words, these studies correlate patients
with a positive LN on imaging to patients with a positive LN
during laparotomy. This carries two important limitations. First,
it is difficult to determine whether the suspicious node on
imaging corresponds to the positive node found during laparo-
tomy. Second, there often is a delay between imaging and
surgery, and LN size may alter during this delay and hamper
accurate measurements of LN size by CT.
Therefore, the aim of the present study was to evaluate the
association between LN size and the presence of metastasis in
patients with HCCA measuring LN size using (low power) micro-
scopical examination. The proportional size of the metastatic
lesion within positive nodes was also evaluated.
Materials and methods
Patients
Histological slides of 147 patients who had undergone exploration
for HCCA with at least one LN available were assessed. Laparoto-
mies were performed from 1992 through to 2010. Patients who
were found to be unresectable during laparotomy were also
included, once at least one lymph node was histologically analy-
sed. In all, 147 patients underwent exploration, of whom 100
patients underwent a resection. Out of the 47 unresectable
patients, 160 LN were assessed, of which 54 (34%) were tumour
positive. In these patients only suspicious (large) LN were
assessed, as a complete lymphadenectomy was not useful, owing
to unresectability. In 100 resected patients, 485 LN were retrieved,
of which 52 (10.7%) were tumour positive. Patients and operation
characteristics are shown in Table 1.
Lymph nodes
In the first years of this study (until 2000), LN were not rou-
tinely harvested and only suspicious LN were removed and
assessed. In the last decade a complete lymphadenectomy of the
hepatoduodenal ligament was routinely performed, which was
extended along the common hepatic artery until the celiac axis.
Isolated LN were sent to the pathology department or dissected
from the specimen by the pathologist according to a standard-
ized protocol. Biopsies of LN were excluded, and only complete
LN were assessed. The specimens were fixed in 5% formaldehyde
and embedded in paraffin. Grossly enlarged LN that could not
be embedded in one single block were measured before process-
ing and recorded in the pathology report. The size (maximum
diameter and short-axis diameter) of each single node was
retrieved from the report or measured from the pathological
section on the glass slide. The separation of individual LN in
clusters of para-aortic LN was difficult macroscopically, however,
microscopically these LN could well be distinguished from each
other. Images of the histological sections were acquired with a
stereo microscope (model M165 FC; Leica Microsystems,
Wetzlar, Germany) equipped with a 1.0 ¥ Planapo objective and
a digital camera (model DFC 425C, Leica). The maximum diam-
eter of the LN was measured offline using a calibrated ruler inte-
grated in the software (Leica Application Suite) (Fig. 1). All LN
were microscopically re-evaluated for the presence of metastasis;
this analysis was carried out by an experienced hepatobiliary
pathologist (F.Jt.K.). When a metastatic lesion was detected, the
proportion of the metastatic lesion in relation to the LN was
estimated and recorded.
Statistical analysis
Statistical analysis was performed with the Statistical Package for
Social Sciences (version 16.0.2.1; SPSS Inc., Chicago, IL, USA).
Continuous data were compared using an independent sample
t-test, and are expressed as means  SD. Frequencies were analy-
sed using the c2 test. A receiver-operating characteristic (ROC)
curve analysis was performed. All statistical tests were two-tailed,
and were evaluated at the 5% level of significance.
Table 1 Characteristics of hilar cholangiocarcinoma (HCCA) patients
who underwent a laparotomy from 1992 through to 2010
Patients
(n = 147)
Patient details
Male 94 (64)
Female 53 (36)
Age (median) 25–78 (62)
Bismuth–Corlette classification
Type 1 or 2 38 (26)
Type 3a 57 (38)
Type 3b 32 (22)
Type 4 20 (14)
Resection performed
Yes 100 (68)
No 47 (32)
LN
Total 645 (100)
Negative LN 539 (84)
Positive LN 106 (16)
N0 patients 93 (63)
N1 patients 54 (37)
Average LN evaluated per patient 4.4
Size in mm. (mean) 11.3
LN, lymph node.
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Results
Correlation of LN metastasis and size?
Out of the 147 surgical specimens, 645 LN were retrieved and the
axial size was measured. One hundred and six nodes (16%)
showed evidence of metastasis. LN harbouring metastatic cancer
cells were significantly larger when compared with negative LN
(mean 14.85  0.85 mm vs. 10.65  0.31 mm, P < 0.001).
Determing a clinically useful cut-off point
The commonly used cut-off point in daily clinical practice for
assessing nodal involvement is 10 mm. Out of 323 LN smaller
than 10 mm, 32 (10%) showed metastatic involvement (Table 2).
Out of 322 LN of 10 mm or larger, 74 (23%) were metastatically
involved.
In order to further determine the chance of metastatic involve-
ment based on size, we examined the frequency of metastatically
involved LN in different size groups (i.e. 0–4 mm, 5–9 mm,
10–19 mm, 20–29 mm, >30 mm). As shown in Table 2, the pro-
portion of metastically involved LN increased from 8% in the <
5 mm group to 37% in the >30 mm group (P < 0.001).
To determine the optimal cut-off point of the nodal size a ROC
curve was constructed (Fig. 2). The area under the curve (AUC) of
the ROC curve was 0.658, with P < 0.001, testing whether the AUC
> 0.50. As shown in Table 3, a cut-off of 12.5 mm in LN diam-
eter could predict the presence of metastatic involvement with a
sensitivity and specificity of 52% and 70%, respectively.
Also the short-axis diameter was measured as shown in Table 4.
The proportion of positive LN was 9% in LN with a short-axis
diameter smaller than 6 mm, and increased to 28% in LN with a
short-axis diameter bigger than 19 mm. Hence, the results of
short-axis diameters are similar to maximum diameter results.
Figure 1 Pathological section of the lymph node (LN) on the glass
slide. The maximum diameter and short axis diameter of the LN were
measured off-line using a calibrated ruler integrated in the software
Table 2 Lymph node (LN) classified according to size
Negative lnn (%) Positive lnn (%) Total
Lymph node size
<10 mm 291 (90) 32 (10) 323
10 mm 248 (77) 74 (23) 322
<5 mm 150 (92) 13 (8) 163
5–9 mm 177 (88) 24 (12) 201
10–19 mm 159 (76) 50 (24) 209
20–29 mm 36 (80) 9 (20) 45
>30 mm 17 (63) 10 (37) 27
Total 539 (84) 106 (16) 645
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Figure 2 Receiver-operating characteristic (ROC)-curve of lymph
node (LN) size to determine LN metastasis in hilar cholangiocarci-
noma (HCCA) [area under the curve (AUC) = 0.658; P < 0.001, testing
whether the AUC > 0.50]
Table 3 Sensitivity and specificity of several cut-off values for pre-
dicting lymph node (LN) positivity according to size
Sensitivity Specificity
Cut-off value
4.5 mm 93 19
9.5 mm 70 54
10.5 mm 65 61
12.5 mm 52 70
14.5 mm 42 75
16.5 mm 32 83
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The proportion of metastatic cells within the LN
The proportion of malignant lesions in relation to the whole
LN was estimated in all positive LN. As shown in Table 5, in half
of the positive LN, the area of metastatic cells was 10% or less of
the total LN. Hence, a needle biopsy of LN with 10% or less
metastatic involvement could lead to a high incidence of false-
negative results owing to a sampling error.
The effect of LN size on the proportion of metastatic cells
within the LN was evaluated (Table 6). Hypothetically, tumour
growth would increase the size of metastically involved LN.
Thus, LN with a larger diameter would harbour a larger propor-
tion of metastatic cells. Yet, as shown in Table 6, LN size did not
correlate with the proportion of metastatic cells within the LN
(P = 0.31).
Discussion
The present study is the first to investigate directly the correla-
tion between sizes of LN and the chance of metastatic infiltra-
tion in HCCA patients. We found that while metastatically
involved LN of HCCA are significantly larger when compared
with negative LN, the clinical usefulness of lymph node size is
doubtful. Whereas only 23% of LN larger than 10 mm were
involved with metastatic cells, 10% of LN smaller than 10 mm
harboured metastatic cells. The highest chance of metastatic
involvement was found in LN larger than 30 mm. However, this
size category comprised no more than 4% of all nodes and the
overall metastatic involvement in this group was only 37%. The
relatively small AUC of the ROC curve of 0.66 also suggests that
nodal size is not useful in predicting LN metastasis.
Noji et al. investigated the relationship of size and metastatic
involvement in patients with biliary cancer based on CT crite-
ria.17,18 The authors concluded that CT is not clinically useful for
nodal staging in patients with biliary cancer owing to the lack of a
correlation between LN size and metastatic infiltration. This is in
accordance with our results, and we believe the present study also
shows that any imaging modality will not be able to accurately
predict metastatic infiltration based on nodal size alone. Other
imaging criteria, such as nodal shape or signs of necrosis, could be
more specific for metastatic infiltration. In addition, high-
resolution MRI with superparamagnetic nanoparticles may be a
promising method to identify LN metastasis19 in patients with
HCCA.
The relationship between LN size and metastatic involvement
has been investigated in various tumours, including uterine,
breast, gastric, oesophageal and colorectal cancer.20–26 Similar
results were found in these previous studies regarding the lack of
clinical usefulness of LN size as predictor of metastatic involve-
ment. The size of the LN found in the present study was large
(mean 11.3 mm) in comparison to the LN in colorectal, uterine
and gastric cancer (mean size 2.7 to 6.0 mm).20,21,23,24,27 This
finding supports our assumption that perihilar LN in patients
with HCCA are on average larger as a result of frequent, concomi-
tant local inflammation and cholangitis. This also may have influ-
enced the low correlation found between LN size and metastatic
involvement in the present study.
The question remains whether the size after fixation and stain-
ing can be extrapolated to the size on imaging modalities. We have
not performed imaging on resections specimens, which would
ideally confirm the size relation between imaging size and mea-
surement after fixation. Yet, Monig et al. did perform imaging on
resections specimens, and thereby found a shrinkage factor of LN
as a result of fixation and staining, which was calculated to be
10%.23 Taking into account a 10% shrinkage factor, 9% (25/255)
of LN smaller than 10 mm were metastatically involved, whereas
22% (81/284) of LN of 10 mm or larger showed metastasis.
Hence, results remain approximately the same when applying this
shrinkage factor. We therefore believe that shrinkage as a result of
fixation and staining was not a significant issue in the present
study.
We also investigated the proportion of the metastatic lesion
with regard to LN size. We found that half of the LN investigated,
were 10% or less involved with metastatic cells. As a consequence,
the chance of missing malignant cells in a metastatic LN using a
needle biopsy is significant, which could be one of the factors
leading to false negatives in these patients. Although the present
study was not designed to assess this question, we believe that
caution is warranted when performing a nodal biopsy. Nonethe-
less, the only study addressing this topic by Gleeson et al28 found
metastases in LN of 8/47 (17%) patients with unresectable HCCA
using endoscopic ultrasound (EUS)-guided fine needle aspiration
Table 4 Lymph node (LN) classified according to size in short-axis
diameter
Negative lnn (%) Positive lnn (%) Total
LN size
<10 mm 416 (87) 64 (13) 480
10 mm 123 (75) 42 (26) 165
<6 mm 270 (91) 27 (9) 297
6–9 mm 146 (80) 37 (20) 183
10–19 mm 103 (75) 34 (25) 137
>19 mm 20 (71) 8 (29) 28
Total 539 (84) 106 (16) 645
Table 5 Metastatically involved lymph node (LN) and the proportion
of involvement
Percentage involvement LN (%)
5% 29 (27)
10% 24 (22)
15–45% 23 (20)
50% 30 (28)
Total 106
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(FNA) and missed only two patients with malignant perigastric
LN.
A major drawback of the present study design was the unavail-
ability of the ‘small’ LN of the unresectable patients, which where
not removed owing to the unresectability. However, if we had
chosen to exclude these patients, we would have introduced
another major bias in the present study. We would then have
excluded a group of patients with a large proportion of positive
LN, thus resulting in a study group with a significantly lower
proportion of positive LN, which is not representative of the clini-
cal situation. When we analysed the LN sizes of only resectable
patients, the relation of size and metastatic involvement is even
worse, as shown in Table 7. Hence, we believe the above-
mentioned bias will not affect our conclusions.
In conclusion, no clear cut-off point of LN size (maximum
diameter, or short-axis diameter) in HCCA patients was found
that could accurately predict nodal involvement. This finding
has several implications. First, imaging studies should not rely
only on LN size in predicting LN metastasis, and different
imaging criteria should be used in addition to size criteria. And
second, during a laparotomy, one cannot rely on nodal size alone
when assessing nodal status. Furthermore, in 50% of the
positive LN the metastatic lesion accounted for 10% or less of
LN size. Consequently, the chance of missing malignant cells
when performing a needle biopsy in positive LN should be
considered.
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